GlobalData on MSN4h
Boston Scientific reports outcomes from trial of LAAC deviceThe trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.
48m
Boston Scientific (BSX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Travis Steed ...
What’s Causing Boston Scientific Corporation (BSX) Stock’s 16.53% Jump Over the Last Six Months?
On Friday, Boston Scientific Corporation (BSX) stock saw a decline, ending the day at $86.99 which represents a decrease of $-0.60 or -0.69% from the prior close of $87.59. The stock opened at $87.12 ...
Marie Thibault, an analyst from BTIG, maintained the Buy rating on Boston Scientific (BSX – Research Report). The associated price target ...
Boston Scientific (NYSE:BSX) announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX ...
Boston Scientific (NYSE: BSX) today announced the completion of its $3.7 billion acquisition of Axonics, Inc. (Nasdaq: AXNX).
Axonics (NASDAQ:AXNX) quickly edged higher by 0.8% after a Nasdaq delisting notice for its planned sale to Boston Scientific ...
Boston Scientific, a Marlborough medical device manufacturer, has officially closed its acquisition of Axonics Inc. after entering into a purchase agreement in January.
Boston Scientific temporarily paused enrolment in its AVANT GUARD trial in October to “assess a few unanticipated ...
Boston Scientific Corporation's acquisition of Axonics, Inc. for $3.7 billion expands urology offerings with innovative ...
Expanding its portfolio further into cardiovascular health, Marlborough medical device manufacturer Boston Scientific has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback